National Bank of Canada FI Increases Holdings in Boston Scientific Corporation $BSX

National Bank of Canada FI increased its position in Boston Scientific Corporation (NYSE:BSX) by 16.9% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,642,213 shares of the medical equipment provider’s stock after buying an additional 237,912 shares during the quarter. National Bank of Canada FI’s holdings in Boston Scientific were worth $160,325,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the second quarter worth approximately $26,000. Steph & Co. purchased a new stake in shares of Boston Scientific in the 3rd quarter valued at $25,000. Murphy & Mullick Capital Management Corp boosted its stake in shares of Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 170 shares in the last quarter. Financial Consulate Inc. bought a new position in shares of Boston Scientific during the 3rd quarter valued at $25,000. Finally, United Community Bank raised its position in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Up 0.9%

Shares of BSX opened at $69.77 on Tuesday. The stock has a market capitalization of $103.53 billion, a P/E ratio of 35.96, a PEG ratio of 0.97 and a beta of 0.69. Boston Scientific Corporation has a twelve month low of $67.56 and a twelve month high of $109.50. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The firm has a fifty day simple moving average of $81.95 and a two-hundred day simple moving average of $92.95.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The company’s revenue for the quarter was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, research analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Transactions at Boston Scientific

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research firms have weighed in on BSX. Argus raised shares of Boston Scientific to a “strong-buy” rating in a research note on Thursday, February 26th. JPMorgan Chase & Co. reduced their price objective on Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Royal Bank Of Canada lowered their target price on Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Robert W. Baird dropped their target price on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, February 5th. Finally, TD Cowen reduced their price target on Boston Scientific from $115.00 to $100.00 and set a “buy” rating on the stock in a research report on Monday, February 2nd. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $108.00.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analysis arguing the stock’s pullback may be overdone given solid fundamentals and recent financial results, which helps explain why investors are buying despite legal headlines. Is Boston Scientific Corp. (BSX) Pull Back Overdone as Financial Results Impress?
• Negative Sentiment: Multiple securities class actions and investor notices allege Boston Scientific misled investors about growth and competitive risks in its U.S. Electrophysiology segment; law firms are soliciting lead-plaintiff applicants ahead of a May 4, 2026 deadline, increasing potential litigation exposure and headline risk. Boston Scientific Lawsuits Put Electrophysiology Outlook And Valuation In Focus
• Negative Sentiment: Rosen Law Firm reminder: purchasers of BSX between July 23, 2025 and Feb 3, 2026 have until May 4, 2026 to seek lead-plaintiff status in the securities fraud action — more publicity and potential consolidation of claims. BSX Investors Have Opportunity to Lead Boston Scientific Corporation Securities Fraud Lawsuit
• Negative Sentiment: Faruqi & Faruqi issues an investor reminder about the same May 4 deadline and is investigating potential claims tied to disclosures during the Class Period — another firm adding legal resources and publicity. BSX INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
• Negative Sentiment: Robbins Geller Rudman & Dowd notifies investors with substantial losses about opportunities to lead a class action, repeating allegations that the company misled investors on its U.S. EP segment — amplifies potential class consolidation and damages exposure. INVESTOR NOTICE: Boston Scientific Corporation Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
• Negative Sentiment: Several other plaintiff firms (Glancy Prongay Wolke & Rotter; Bronstein Gewirtz & Grossman; additional Rosen/Faruqi notices) have filed or circulated similar investor-alerts — increasing the odds of coordinated litigation activity and legal costs for BSX. ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Boston Scientific Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – BSX

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.